Which has higher valuation and earnings, NEOG or CERS?

Cerus has lower revenue, but higher earnings than Neogen. Cerus is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neogen $894.66M 2.44 -$1.09B -$2.80 N/A Cerus $206.13M 3.06 -$15.63M -$0.05 N/A

Is NEOG or CERS more profitable?

Cerus has a net margin of -4.41% compared to Neogen's net margin of -69.93%. Neogen's return on equity of 2.35% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Neogen -69.93% 2.35% 1.46% Cerus -4.41% -15.18% -4.38%

Does the media prefer NEOG or CERS?

In the previous week, Neogen had 7 more articles in the media than Cerus. MarketBeat recorded 9 mentions for Neogen and 2 mentions for Cerus. Cerus' average media sentiment score of 0.76 beat Neogen's score of 0.59 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neogen 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is STAA or CERS more profitable?

Cerus has a net margin of -4.41% compared to STAAR Surgical's net margin of -7.24%. STAAR Surgical's return on equity of 3.31% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets STAAR Surgical -7.24% 3.31% 2.55% Cerus -4.41% -15.18% -4.38%

Does the media prefer STAA or CERS?

In the previous week, STAAR Surgical had 9 more articles in the media than Cerus. MarketBeat recorded 11 mentions for STAAR Surgical and 2 mentions for Cerus. Cerus' average media sentiment score of 0.76 beat STAAR Surgical's score of 0.03 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STAAR Surgical 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is QDEL or CERS more profitable?

Cerus has a net margin of -4.41% compared to QuidelOrtho's net margin of -45.57%. QuidelOrtho's return on equity of 4.25% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets QuidelOrtho -45.57% 4.25% 1.56% Cerus -4.41% -15.18% -4.38%

Does the media refer more to QDEL or CERS?

In the previous week, QuidelOrtho had 1 more articles in the media than Cerus. MarketBeat recorded 3 mentions for QuidelOrtho and 2 mentions for Cerus. Cerus' average media sentiment score of 0.76 beat QuidelOrtho's score of 0.54 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OSUR or CERS more profitable?

Cerus has a net margin of -4.41% compared to OraSure Technologies' net margin of -66.42%. Cerus' return on equity of -15.18% beat OraSure Technologies' return on equity. Company Net Margins Return on Equity Return on Assets OraSure Technologies -66.42% -18.57% -15.71% Cerus -4.41% -15.18% -4.38%

Does the media refer more to OSUR or CERS?

In the previous week, Cerus had 1 more articles in the media than OraSure Technologies. MarketBeat recorded 2 mentions for Cerus and 1 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 1.11 beat Cerus' score of 0.76 indicating that OraSure Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OraSure Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CERS or UTMD?

Cerus presently has a consensus price target of $4.00, indicating a potential upside of 26.98%. Given Cerus' stronger consensus rating and higher possible upside, equities analysts plainly believe Cerus is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cerus 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Cerus (CERS) Competitors

$3.15 +0.02 (+0.64%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$3.18 +0.04 (+1.11%)

As of 07/20/2026 07:54 PM Eastern

Compare

CERS vs. NEOG, STAA, QDEL, OSUR, and UTMD

Should you buy Cerus stock or one of its competitors? MarketBeat compares Cerus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cerus include Neogen (NEOG), STAAR Surgical (STAA), QuidelOrtho (QDEL), OraSure Technologies (OSUR), and Utah Medical Products (UTMD). These companies are all part of the "health care supplies" industry.

How does Cerus compare to Neogen?

Neogen (NASDAQ:NEOG) and Cerus (NASDAQ:CERS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Cerus has a net margin of -4.41% compared to Neogen's net margin of -69.93%. Neogen's return on equity of 2.35% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neogen	-69.93%	2.35%	1.46%
Cerus	-4.41%	-15.18%	-4.38%

Neogen presently has a consensus target price of $10.67, indicating a potential upside of 6.56%. Cerus has a consensus target price of $4.00, indicating a potential upside of 26.98%. Given Cerus' stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Cerus has lower revenue, but higher earnings than Neogen. Cerus is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neogen	$894.66M	2.44	-$1.09B	-$2.80	N/A
Cerus	$206.13M	3.06	-$15.63M	-$0.05	N/A

96.7% of Neogen shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 0.6% of Neogen shares are owned by company insiders. Comparatively, 5.3% of Cerus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Neogen has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, Cerus has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

In the previous week, Neogen had 7 more articles in the media than Cerus. MarketBeat recorded 9 mentions for Neogen and 2 mentions for Cerus. Cerus' average media sentiment score of 0.76 beat Neogen's score of 0.59 indicating that Cerus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neogen	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cerus beats Neogen on 8 of the 15 factors compared between the two stocks.

How does Cerus compare to STAAR Surgical?

STAAR Surgical (NASDAQ:STAA) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Cerus has a net margin of -4.41% compared to STAAR Surgical's net margin of -7.24%. STAAR Surgical's return on equity of 3.31% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STAAR Surgical	-7.24%	3.31%	2.55%
Cerus	-4.41%	-15.18%	-4.38%

STAAR Surgical currently has a consensus price target of $27.81, indicating a potential upside of 16.03%. Cerus has a consensus price target of $4.00, indicating a potential upside of 26.98%. Given Cerus' stronger consensus rating and higher possible upside, analysts plainly believe Cerus is more favorable than STAAR Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STAAR Surgical	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

96.7% of STAAR Surgical shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 39.9% of STAAR Surgical shares are held by company insiders. Comparatively, 5.3% of Cerus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cerus has lower revenue, but higher earnings than STAAR Surgical. Cerus is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STAAR Surgical	$239.44M	4.98	-$80.45M	-$0.43	N/A
Cerus	$206.13M	3.06	-$15.63M	-$0.05	N/A

In the previous week, STAAR Surgical had 9 more articles in the media than Cerus. MarketBeat recorded 11 mentions for STAAR Surgical and 2 mentions for Cerus. Cerus' average media sentiment score of 0.76 beat STAAR Surgical's score of 0.03 indicating that Cerus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STAAR Surgical	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

STAAR Surgical has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market. Comparatively, Cerus has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Summary

STAAR Surgical beats Cerus on 9 of the 16 factors compared between the two stocks.

How does Cerus compare to QuidelOrtho?

QuidelOrtho (NASDAQ:QDEL) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 1.1% of QuidelOrtho shares are held by insiders. Comparatively, 5.3% of Cerus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cerus has a net margin of -4.41% compared to QuidelOrtho's net margin of -45.57%. QuidelOrtho's return on equity of 4.25% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-45.57%	4.25%	1.56%
Cerus	-4.41%	-15.18%	-4.38%

Cerus has lower revenue, but higher earnings than QuidelOrtho. Cerus is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.41	-$1.13B	-$17.82	N/A
Cerus	$206.13M	3.06	-$15.63M	-$0.05	N/A

QuidelOrtho has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Cerus has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

In the previous week, QuidelOrtho had 1 more articles in the media than Cerus. MarketBeat recorded 3 mentions for QuidelOrtho and 2 mentions for Cerus. Cerus' average media sentiment score of 0.76 beat QuidelOrtho's score of 0.54 indicating that Cerus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

QuidelOrtho presently has a consensus target price of $13.63, suggesting a potential downside of 17.82%. Cerus has a consensus target price of $4.00, suggesting a potential upside of 26.98%. Given Cerus' stronger consensus rating and higher probable upside, analysts clearly believe Cerus is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	2 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Cerus beats QuidelOrtho on 10 of the 16 factors compared between the two stocks.

How does Cerus compare to OraSure Technologies?

OraSure Technologies (NASDAQ:OSUR) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

In the previous week, Cerus had 1 more articles in the media than OraSure Technologies. MarketBeat recorded 2 mentions for Cerus and 1 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 1.11 beat Cerus' score of 0.76 indicating that OraSure Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OraSure Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cerus has higher revenue and earnings than OraSure Technologies. Cerus is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OraSure Technologies	$115.02M	2.30	-$68.73M	-$1.04	N/A
Cerus	$206.13M	3.06	-$15.63M	-$0.05	N/A

93.5% of OraSure Technologies shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 4.7% of OraSure Technologies shares are held by company insiders. Comparatively, 5.3% of Cerus shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cerus has a net margin of -4.41% compared to OraSure Technologies' net margin of -66.42%. Cerus' return on equity of -15.18% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OraSure Technologies	-66.42%	-18.57%	-15.71%
Cerus	-4.41%	-15.18%	-4.38%

OraSure Technologies has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market. Comparatively, Cerus has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

OraSure Technologies currently has a consensus price target of $3.00, suggesting a potential downside of 22.08%. Cerus has a consensus price target of $4.00, suggesting a potential upside of 26.98%. Given Cerus' stronger consensus rating and higher possible upside, analysts plainly believe Cerus is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Cerus beats OraSure Technologies on 13 of the 16 factors compared between the two stocks.

How does Cerus compare to Utah Medical Products?

Cerus (NASDAQ:CERS) and Utah Medical Products (NASDAQ:UTMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Utah Medical Products has lower revenue, but higher earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	3.06	-$15.63M	-$0.05	N/A
Utah Medical Products	$38.52M	5.72	$11.29M	$3.38	20.50

Cerus has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Utah Medical Products has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

Cerus presently has a consensus price target of $4.00, indicating a potential upside of 26.98%. Given Cerus' stronger consensus rating and higher possible upside, equities analysts plainly believe Cerus is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

78.4% of Cerus shares are owned by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are owned by institutional investors. 5.3% of Cerus shares are owned by insiders. Comparatively, 8.0% of Utah Medical Products shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Cerus had 2 more articles in the media than Utah Medical Products. MarketBeat recorded 2 mentions for Cerus and 0 mentions for Utah Medical Products. Cerus' average media sentiment score of 0.76 beat Utah Medical Products' score of 0.00 indicating that Cerus is being referred to more favorably in the media.

Company	Overall Sentiment
Cerus	Positive
Utah Medical Products	Neutral

Utah Medical Products has a net margin of 28.90% compared to Cerus' net margin of -4.41%. Utah Medical Products' return on equity of 9.13% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-4.41%	-15.18%	-4.38%
Utah Medical Products	28.90%	9.13%	8.86%

Summary

Cerus and Utah Medical Products tied by winning 8 of the 16 factors compared between the two stocks.

Get Cerus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CERS vs. The Competition

Export

Metric	Cerus	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$627.16M	$8.90B	$6.89B	$12.28B
Dividend Yield	N/A	2.48%	2.67%	9.39%
P/E Ratio	-63.00	16.04	27.07	23.94
Price / Sales	3.06	6.77	515.45	90.30
Price / Cash	N/A	18.55	26.68	47.25
Price / Book	9.26	3.26	10.42	6.14
Net Income	-$15.63M	$230.22M	$3.60B	$331.74M
7 Day Performance	2.61%	-1.77%	-1.26%	-1.81%
1 Month Performance	16.67%	-1.97%	1.07%	-1.44%
1 Year Performance	128.26%	-0.92%	23.61%	16.33%

Cerus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CERS Cerus	3.1985 of 5 stars	$3.15 +0.6%	$4.00 +27.0%	+131.6%	$627.16M	$206.13M	N/A	290
NEOG Neogen	1.2151 of 5 stars	$9.60 -0.6%	$10.67 +11.2%	+111.2%	$2.09B	$894.66M	N/A	2,110
STAA STAAR Surgical	2.9873 of 5 stars	$27.30 -1.7%	$27.81 +1.9%	+38.1%	$1.36B	$239.44M	N/A	1,211
QDEL QuidelOrtho	2.1211 of 5 stars	$17.39 -2.8%	$13.63 -21.7%	-34.9%	$1.19B	$2.73B	N/A	6,500
OSUR OraSure Technologies	1.5963 of 5 stars	$4.32 +0.3%	$3.00 -30.5%	+20.3%	$296.81M	$115.02M	N/A	840	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CERS) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cerus (CERS) Competitors

CERS vs. NEOG, STAA, QDEL, OSUR, and UTMD

How does Cerus compare to Neogen?

Summary

How does Cerus compare to STAAR Surgical?

Summary

How does Cerus compare to QuidelOrtho?

Summary

How does Cerus compare to OraSure Technologies?

Summary

How does Cerus compare to Utah Medical Products?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERS vs. The Competition

Cerus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cerus (CERS) Competitors

CERS vs. NEOG, STAA, QDEL, OSUR, and UTMD

How does Cerus compare to Neogen?

Is NEOG or CERS more profitable?

Do analysts rate NEOG or CERS?

Which has higher valuation and earnings, NEOG or CERS?

Do insiders & institutionals hold more shares of NEOG or CERS?

Which has more risk and volatility, NEOG or CERS?

Does the media prefer NEOG or CERS?

Summary

How does Cerus compare to STAAR Surgical?

Is STAA or CERS more profitable?

Do analysts prefer STAA or CERS?

Do insiders & institutionals hold more shares of STAA or CERS?

Which has preferable valuation and earnings, STAA or CERS?

Does the media prefer STAA or CERS?

Which has more volatility and risk, STAA or CERS?

Summary

How does Cerus compare to QuidelOrtho?

Do institutionals and insiders believe in QDEL or CERS?

Is QDEL or CERS more profitable?

Which has higher valuation and earnings, QDEL or CERS?

Which has more volatility & risk, QDEL or CERS?

Does the media refer more to QDEL or CERS?

Do analysts prefer QDEL or CERS?

Summary

How does Cerus compare to OraSure Technologies?

Does the media refer more to OSUR or CERS?

Which has preferable earnings and valuation, OSUR or CERS?

Do institutionals and insiders believe in OSUR or CERS?

Is OSUR or CERS more profitable?

Which has more risk and volatility, OSUR or CERS?

Do analysts recommend OSUR or CERS?

Summary

How does Cerus compare to Utah Medical Products?

Which has higher earnings and valuation, CERS or UTMD?

Which has more volatility and risk, CERS or UTMD?

Do analysts recommend CERS or UTMD?

Do institutionals and insiders have more ownership in CERS or UTMD?

Does the media prefer CERS or UTMD?

Is CERS or UTMD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERS vs. The Competition

Cerus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools